Ticagrelor use in acute myocardial infarction: Balancing evidence‐based medicine with affordability
| Autor: | Teshia Sorensen, Andrew L. Walker, Jack Morshedzadeh, Rashmee U. Shah, Tyler Sledge, Theophilus Owan, Paolo P. Gabriel |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome business.industry Pharmaceutical Science Retrospective cohort study Pharmacy medicine.disease Clopidogrel Article law.invention Randomized controlled trial law Interquartile range Relative risk Emergency medicine medicine Pharmacology (medical) cardiovascular diseases Myocardial infarction business Ticagrelor health care economics and organizations medicine.drug |
| Zdroj: | JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 1:58-61 |
| ISSN: | 2574-9870 |
| DOI: | 10.1002/jac5.1010 |
| Popis: | STUDY OBJECTIVE: Data from randomized controlled trials support a mortality benefit with ticagrelor versus clopidogrel among patients with acute myocardial infarction (AMI). Many healthcare providers preferentially treat patients with AMI with ticagrelor. The goal of this study was to determine the association between out-of-pocket drug costs and ticagrelor continuation compared with switching to clopidogrel among patients hospitalized for AMI, following a pharmacist-led discussion on outpatient co-payment costs for ticagrelor. DESIGN: Retrospective cohort study. SETTING: A tertiary care academic medical center. PATIENTS: Patients hospitalized with AMI between February 15, 2015 and January 23, 2017, who were loaded with ticagrelor on presentation. MAIN RESULTS: Of 143 patients with AMI loaded with ticagrelor, 70 (49%) switched to clopidogrel after cost discussion. The median monthly ticagrelor co-payment was $268.29 (interquartile range [IQR] $45–$350) for switchers, versus $18 (IQR $6–$24) for non-switchers (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text